Retrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-Resistant<i>Staphylococcus aureus</i>Complicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid

Wright, Bradley M.; Eiland, Edward H.

doi:10.4061/2011/347969

Cited by 10 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[9][10][11][12]14,[63][64][65][66][67][68][69][70][71][72][73] Vancomycin is effective and often used against MRSA cSSTIs in the hospital. Empiric therapy with vancomycin has increased from 2000 (18%) to 2006 (93%).…”

Section: Treatment Failurementioning

confidence: 99%

Hospitalist Perspective on the Treatment of Skin and Soft Tissue Infections

Amin

Cerceo

Deitelzweig

et al. 2014

Mayo Clinic Proceedings

View full text Add to dashboard Cite

The prevalence of skin and soft tissue infections (SSTIs) has been increasing in the United States. These infections are associated with an increase in hospital admissions. Hospitalists play an increasingly important role in the management of these infections and need to use hospital resources efficiently and effectively. When available, observation units are useful for treating low-risk patients who do not require hospital admission. Imaging tools may help to exclude abscesses and necrotizing soft tissue infections; however, surgical exploration remains the principal means of diagnosing necrotizing soft tissue infections. The most common pathogens that cause SSTIs are streptococci and Staphylococcus aureus. Methicillin-resistant S aureus (MRSA) is a prevalent pathogen, and concerns are increasing regarding the unclear distinctions between community-acquired and hospital-acquired MRSA. Other less frequent pathogens that cause SSTIs include Enterococcus species, Escherichia coli, Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa. Cephalexin and clindamycin are suitable options for infections caused by streptococcal species and methicillin-susceptible S aureus. The increasing resistance of S aureus and Streptococcus pyogenes to erythromycin limits its use in these infections, and better alternatives are available. Parenteral cefazolin, nafcillin, or oxacillin can be used in hospitalized patients with nonpurulent cellulitis caused by streptococci and methicillin-susceptible S aureus. When oral MRSA therapy is indicated, clindamycin, doxycycline, trimethoprim-sulfamethoxazole, or linezolid is appropriate. Vancomycin, linezolid, daptomycin, tigecycline, telavancin, and ceftaroline fosamil are intravenous options that should be used in MRSA infections that require patient hospitalization. In the treatment of patients with SSTIs, hospitalists are at the forefront of providing proper patient care that reduces hospital costs, duration of therapy, and therapeutic failures. This review updates guidelines on the management of SSTIs with a focus on infections caused by S aureus, particularly MRSA, and outlines the role of the hospitalist in the effective management of SSTIs.

show abstract

Section: Treatment Failurementioning

confidence: 99%

Hospitalist Perspective on the Treatment of Skin and Soft Tissue Infections

Amin

Cerceo

Deitelzweig

et al. 2014

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…Using the drugs in Box 1 as search terms, we identified 41 records. Of these, 12 were excluded, three studies were published in a non-English language 9 – 11 , one did not concern any of the new drugs 12 and eight did not link costs and effects explicitly 13 – 20 . Hence, an initial 29 studies were included for review ( 21 – 48 , 58 , 58).…”

Section: Cost-effectiveness Of New Antibacterial Agentsmentioning

confidence: 99%

Cost‐effectiveness and Pricing of Antibacterial Drugs

Verhoef

Morris

2014

Chem Biol Drug Des

View full text Add to dashboard Cite

Growing resistance to antibacterial agents has increased the need for the development of new drugs to treat bacterial infections. Given increasing pressure on limited health budgets, it is important to study the cost-effectiveness of these drugs, as well as their safety and efficacy, to find out whether or not they provide value for money and should be reimbursed. In this article, we systematically reviewed 38 cost-effectiveness analyses of new antibacterial agents. Most studies showed the new antibacterial drugs were cost-effective compared to older generation drugs. Drug pricing is a complicated process, involving different stakeholders, and has a large influence on cost-effectiveness. Value-based pricing is a method to determine the price of a drug at which it can be cost-effective. It is currently unclear what the influence of value-based pricing will be on the prices of new antibacterial agents, but an important factor will be the definition of ‘value’, which as well as the impact of the drug on patient health might also include other factors such as wider social impact and the health impact of disease.

show abstract

“…[59][60][61] In a retrospective analysis of clinical and cost outcomes associated with MRSA, cSSI treated with daptomycin, vancomycin, or linezolid, the length of hospitalization was slightly shorter in the daptomycin group. 62 Thus, although data from randomized controlled clinical trials comparing outpatient use of daptomycin to oral linezolid are lacking, daptomycin has a major role in the treatment of STTIs in the outpatient practice. 57…”

Section: The Role Of Daptomycin In Treatment Of Sttis In the Outpatiementioning

confidence: 99%

Pharmacological Agents for the Treatment of Skin and Soft Tissue Infections: What is the Role for Daptomycin?

Kelesidis¹

2014

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Skin and soft tissue infections (SSTIs) have increasing prevalence in clinical practice. The emergence of resistant pathogens and especially methicillin-resistant Staphylococcus aureus (MRSA) has led to an increase in the number of hospitalizations due to SSTIs. Daptomycin has been shown to achieve good concentrations in skin and soft tissues and is effective and safe for the treatment of SSTIs. In this review, I summarize the scientific evidence regarding the role of daptomycin in therapy of SSTIs, comparing daptomycin with other antimicrobial agents.

show abstract

Retrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-ResistantStaphylococcus aureusComplicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid

Cited by 10 publications

References 19 publications

Hospitalist Perspective on the Treatment of Skin and Soft Tissue Infections

Hospitalist Perspective on the Treatment of Skin and Soft Tissue Infections

Cost‐effectiveness and Pricing of Antibacterial Drugs

Pharmacological Agents for the Treatment of Skin and Soft Tissue Infections: What is the Role for Daptomycin?

Contact Info

Product

Resources

About